TY - JOUR
AU1 - Stroszczynski, Christian
AU2 - Jost, Dominik
AU3 - Reichardt, Peter
AU4 - Chmelik, Petra
AU5 - Gaffke, Gunnar
AU6 - Kretzschmar, Albrecht
AU7 - Schneider, Ulrike
AU8 - Felix, Roland
AU9 - Hohenberger, Peter
AB - Typical MRI findings for gastro-intestinal stromal tumours (GIST) under treatment with imatinib were evaluated. MRI was performed in 45 patients (25 responders, 20 non-responders) with metastatic or locally advanced, unresectable GIST. Target lesions were selected and re-evaluated after 2, 4, and 6 months of therapy with imatinib. The target tumour response (TTR) was classified according to RECIST criteria. TTR, signal intensity in the centre and border of the lesion and the presence and the extension of a hypervascular rim were analysed. The mean diameter of the marker lesions decreased significantly (P<0.001) from 7.1±2.6 cm to 5.9±2.3 cm after 6 months. Accuracy of RECIST criteria was 51%, 69% and 73% on MRI 2, 4 and 6 months for response assessment. In addition, responders had higher signal-to-noise ratios on T2-w images after 2 months (P<0.05) and a decrease of vascularised areas in the lesion 4 and 6 months after treatment (each P<0.01), when compared with non-responders. Beyond the size measurement for response assessment, MRI provides additional information of tumour response using SI of T2-w images and quantification of vascularised areas of GIST manifestations.
TI - Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI
JF - European Radiology
DO - 10.1007/s00330-005-2867-x
DA - 2005-08-13
UR - https://www.deepdyve.com/lp/springer-journals/follow-up-of-gastro-intestinal-stromal-tumours-gist-during-treatment-64fENcB5ge
SP - 2448
EP - 2456
VL - 15
IS - 12
DP - DeepDyve
ER -